Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-23
2011-08-23
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021700
Reexamination Certificate
active
08003612
ABSTRACT:
Use of a peptide or pharmaceutical composition comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating APP processing, modulating activity of APP secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease.
REFERENCES:
patent: 5948763 (1999-09-01), Soto-Jara et al.
patent: WO 01/34631 (2001-05-01), None
Castillo et al., “Perlecan Binds to the β-Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains . . . ”, J. Neurochem. 69:2452-2465 (1997).
Chen et al., “A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease”, Nature 408(6815):975-979 (2000).
Fields, G.B. and Noble, R.L, “Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids”, Int. J. Polypeptide Prot. Res. 35:161-214 (1990).
Flood et al., “Amnestic effects in mice of four synthetic peptides homologous to amyloid β protein from patients with . . . ”, Procl. Natl. Acad. Sci. 88:3363-3366 (1991).
Flood et al., “An amyloid β-protein fragment, Aβ[12-28], equipotently impairs post-training memory, processing when injected . . . ”, Brain Research 663:271-276 (1994).
Fukuchi et al., “Increased expression of beta-amyloid protein precursor and microtubule-associated protein tau during . . . ”, J. Neurochem. 8(5):1863-1873 (1992).
Games et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein”, Nature 373:523-527 (1995).
Ghilardi et al., “Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo”, Neuroreport. 7(15-17):2607-11 (1996).
Glenner, G.G. and Wong, C.W., “Alzheimer's Disease: Initial Report of the Purification and Characterisation . . . ”, Biochem Biophys Res Comm 120(3): 885-890 (1984).
Grundke-lqbal et al., “Abnormal phosphorylation of the microtubule—associated protein τ (tau) in Alzheimer . . . ”, Procl. Natl. Acad. Sci. USA 83:4913-4917 (1986).
Haass et al., “The Swedish mutation causes early-onset Alzheimer's Disease by β-secretase cleavage within the secretory pathway”, Nature Medicine 1(12):1291-1296 (1995).
Haass, C. and De Strooper, B., “The presenilins in Alzheimer's disease—proteolysis holds the key”, Science 286(5441):916-9 (1999).
Hardy J., “Framing β-amyloid”, Nature Genetics 1:233-234 (1992).
Harrigan et al., “Beta Amyloid is Neurotoxic in Hippocampal Slice Cultures”, Neurobiology of Aging 16(5):779-789 (1995).
Hsiao et al., “Correlative memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice”, Science 274:99-102 (1996).
Hu et al., “Endoproteolytic Cleavage of FE65 Converts the Adaptor Protein to a Potent Suppressor of the sAPPα Pathway in Primates”, J Biol Chem. 280:12548-12558 (2005).
Husby et al., “Nomenclature of Amyloid and Amyloidosis”, Bull. WHO 71 (1):105-108 (1993).
Janus, et al., “Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease”, Nature 408:979-982 (2000).
Kitaguchi et al., “Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity”, Nature 331:530-532 (1988).
Klafki et al., “Electrophoretic separation of betaA4 peptides (1-40) and (1-42)”, Anal Biochem. 237(1):24-9 (1996).
Kosik et al., “Microtubule-associated protein tau (τ) is a major antigenic component of paired helical filaments . . . ”, Procl. Natl. Acad. Sci. USA 83:4044-4048 (1986).
Kukar et al., “Substrate-targeting gamma-secretase modulators”, Nature 453 (7197):925-9 (2008).
Lee et al., “A-68: A Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau”, Science 251:675-678 (1991).
LeVine III H, “Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution”, Protein Science 2:404-410 (1993).
LeVine III H., “Thioflavine T interacton with amyloid β-sheet structures”, Amyloid: Int. J. Exp. Clin. Invest. 2:1-6 (1995).
Mandybur T., “Cerebral Amyloid Angiopathy: The Vascular Pathology and Complications”, Journal of Neuropathology and Experimental Neurology 45(1):79-90 (1986).
Masters et al., “Amyloid plaque core protein in Alzheimer's disease and Down syndrome”, Proc. Natl. Sci. USA 82:4245-4249 (1985).
Merrifield, B., “Solid Phase Synthesis”, Science 232:341-347 (1986).
Morgan, et al., “Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease”, Nature 408:982-985 (2000).
Murrell et al., “A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease”, Science 254: 97-99 (1991).
Naiki, H. and Nakauki, K. “First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro”, Lab Invest 74(2):374-83 (1996).
Pardridge et al., “Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200-Dalton . . . ”, J. Neurochem. 49(5):1394-1401 (1987).
Pardridge, W.M., “Recent developments in peptide drug delivery to the brain”, Pharmacol Toxicol. 71(1):3-10 (1992).
Pardridge, W.M., “New approaches to drug delivery through the blood-brain barrier”,Trends Biotechnol. 12(6):239-45 (1994).
Permanne et al., “Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease . . . ”, The FASEB Journal Express Article pub Apr. 10, 2002.
Pike et al., “In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity”, Brain Research 563:311-314 (1991).
Pike et al., “Structure-Activity Analyses of β-Amyloid Peptides: Contributions of the β25-35 Region to Aggregation and Neurotoxicity”, J. Neurochem. 64(1):253-265 (1995).
Pluta et al., “Evidence of blood-brain barrier permeability/leakage for circulating human Alzheimer's beta-amyloid-(1-42)-peptide”, Neuroreport.7(7):1261-5 (1996).
Poduslo et al., “Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier”, Neurobiol. Dis. 4:27-34 (1997).
Ponte et al. ,“A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors”, Nature 311:525-527 (1988).
Postina, R., “A closer look at alpha-secretase”, Curr Alzheimer Res. 5 (2):179-86 (2008).
Selkoe, D.J., “Alzheimer's disease: genes, proteins, and therapy”, Physiol Rev. 81(2):741-766 (2001).
Tanzi et al., “Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease”, Nature 331:528-532 (1988).
Van Broeckhoven et al., “Amyloid β Protein Precursor Gene and Hereditary Cerebral Hemorrhage with Amyloidosis (Dutch)”, Science 248:1120-1122 (1990).
Van Bree et al., “Drug transport across the blood-brain barrier. III. Mechanisms and methods to improve drug delivery to the central . . . ”, Pharm. World Sci. 15(1):2-9 (1993).
Yang et al., “A Dominant Role for FE65 (APBB1) in Nuclear Signaling”, J Biol Chem. 281:4207-4214 (2006).
Zlokovic , B., “Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology”, Neurobiol. Dis. 4:23-6 (1997).
Cam Judy A.
Castillo Gerardo
Hu Qubai
Lake Thomas
Nguyen Beth
Bradley Christina
Eagen Rebecca
Proteotech Inc.
LandOfFree
Small peptides for the treatment of Alzheimer's disease and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small peptides for the treatment of Alzheimer's disease and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small peptides for the treatment of Alzheimer's disease and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2763736